1. Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL-class fusion
- Author
-
Simone Stokley, Donna Lancaster, Neha Bhatnagar, Deborah Richardson, Christine J. Harrison, Sujith Samarasinghe, Frederik W. van Delft, John Moppett, Katharine Patrick, Alice Norton, Claire Schwab, Brenda Gibson, Emily Winterman, Anna Castleton, Pamela Kearns, Beki James, Andrew McMillan, Mabrouk S. Madi, Michelle Cummins, Jayashree Motwani, Anthony V. Moorman, Aengus O'Marcaigh, Amrana Qureshi, Ajay Vora, Amy A Kirkwood, Gordon Taylor, Jerry Hancock, and Nick Goulden
- Subjects
Oncology ,Male ,medicine.medical_specialty ,Neoplasm, Residual ,Adolescent ,Oncogene Proteins, Fusion ,medicine.drug_class ,medicine.medical_treatment ,Tyrosine-kinase inhibitor ,Targeted therapy ,03 medical and health sciences ,0302 clinical medicine ,hemic and lymphatic diseases ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Relapse risk ,Child ,Proto-Oncogene Proteins c-abl ,Protein Kinase Inhibitors ,Chemotherapy ,ABL ,business.industry ,Infant ,Hematology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,respiratory tract diseases ,030220 oncology & carcinogenesis ,Child, Preschool ,Lymphoblastic leukaemia ,Female ,business ,Adjuvant ,Tyrosine kinase ,030215 immunology - Abstract
Patients with an ABL-class fusion have a high risk of relapse on standard chemotherapy but are sensitive to tyrosine kinase inhibitors (TKI). In UKALL2011, we screened patients with post-induction MRD ≥1% and positive patients (12%) received adjuvant TKI. As the intervention started during UKALL2011, not all eligible patients were screened prospectively. Retrospective screening of eligible patients allowed the outcome of equivalent ABL-class patients who did and did not receive a TKI in first remission to be compared. ABL-class patients who received a TKI in first remission had a reduced risk of relapse/refractory disease: 0% vs. 63% at four years (P = 0·009).
- Published
- 2020